| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
3,5-Diiodo-L-thyronine targets thyroid hormone receptors and metabolic pathways. As a thyroid hormone metabolite, it may bind to thyroid hormone receptors (TRα and TRβ) and modulate gene expression. It has been studied for its effects on energy metabolism, lipid metabolism, and mitochondrial function. Its activity may differ from that of T3 and T4.
|
|---|---|
| ln Vitro |
In vitro, 3,5-diiodo-L-thyronine has been studied for its effects on metabolism. It may modulate mitochondrial function and energy metabolism. Its binding affinity for thyroid hormone receptors and its effects on gene expression have been characterized. Detailed in vitro data are available from pharmacological studies.
|
| ln Vivo |
In vivo, 3,5-diiodo-L-thyronine has been studied in animal models for its metabolic effects. It has been shown to affect energy expenditure, lipid metabolism, and body weight regulation. Its effects are distinct from those of T3 and T4. It is a naturally occurring thyroid hormone metabolite.
|
| Enzyme Assay |
General protocols for thyroid hormone receptor binding assays use cytosolic or nuclear extracts from cells expressing TRα or TRβ. Extracts are incubated with [125I]T3 or [3H]T3 and varying concentrations of 3,5-diiodo-L-thyronine in binding buffer at 4°C for 16-24 hours. Bound ligand is separated using dextran-coated charcoal or hydroxylapatite. Radioactivity is counted. IC50 values are calculated from competition curves.
|
| Cell Assay |
General protocols for metabolic studies use hepatocytes, adipocytes, or muscle cells. Cells are treated with 3,5-diiodo-L-thyronine at various concentrations (1 nM-10 µM) for 24-48 hours. Oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) are measured using Seahorse analyzers. Gene expression of metabolic markers (PGC-1α, CPT1, UCPs) is measured by RT-qPCR. Lipid accumulation is assessed by Oil Red O staining.
|
| Animal Protocol |
General protocols for in vivo metabolic studies use animal models of obesity or metabolic syndrome. 3,5-Diiodo-L-thyronine is administered orally or intraperitoneally at doses of 0.1-10 mg/kg daily for 1-4 weeks. Body weight, food intake, and energy expenditure are measured. Serum lipid levels (triglycerides, cholesterol, free fatty acids) are measured. Glucose tolerance tests are performed. Tissue samples are collected for histological and biochemical analysis.
|
| ADME/Pharmacokinetics |
3,5-Diiodo-L-thyronine has a molecular weight of 524.03 g/mol (C15H13I2NO4). It is a thyroid hormone metabolite. It is slightly soluble in water and soluble in organic solvents. It is metabolized in the liver and excreted via the kidneys. Its pharmacokinetic properties have been characterized in some studies.
|
| Toxicity/Toxicokinetics |
The toxicity profile of 3,5-diiodo-L-thyronine has not been fully characterized. As a thyroid hormone metabolite, it may have effects on metabolism and cardiovascular function at high doses. The compound should be handled with appropriate safety precautions in the laboratory. Comprehensive toxicological studies are limited.
|
| Additional Infomation |
(2S)-2-amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propionic acid is a derivative of phenylalanine.
3,5-Diiodo-L-thyronine (CAS 1041-01-6) is a thyroid hormone metabolite studied for its metabolic effects. It has no approved therapeutic indications and is not a pharmaceutical drug. It is used primarily as a research compound for studying thyroid hormone metabolism and energy regulation. No clinical trials have been registered for this compound. |
| Molecular Formula |
C15H13I2NO4
|
|---|---|
| Molecular Weight |
525.08
|
| Exact Mass |
524.893
|
| CAS # |
1041-01-6
|
| PubChem CID |
92859
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
2.1±0.1 g/cm3
|
| Boiling Point |
559.4±50.0 °C at 760 mmHg
|
| Melting Point |
255-260 °C (dec.)
|
| Flash Point |
292.1±30.1 °C
|
| Vapour Pressure |
0.0±1.6 mmHg at 25°C
|
| Index of Refraction |
1.726
|
| LogP |
3.78
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
22
|
| Complexity |
365
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1=CC(=CC=C1O)OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I
|
| InChi Key |
ZHSOTLOTTDYIIK-ZDUSSCGKSA-N
|
| InChi Code |
InChI=1S/C15H13I2NO4/c16-11-5-8(7-13(18)15(20)21)6-12(17)14(11)22-10-3-1-9(19)2-4-10/h1-6,13,19H,7,18H2,(H,20,21)/t13-/m0/s1
|
| Chemical Name |
3,5-T2 NSC 90469 (2S)-2-Amino-3-[4-(4-hydroxyphenoxy)-3,5-diiodophenyl]propanoic acid
|
| Synonyms |
3,5-Diiodo-L-thyronine 3,5-T2 NSC 90469 (S)-2-amino-3-(4-(4-hydroxyphenoxy)-3,5-diiodophenyl)propanoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
Ethanol : ~22.22 mg/mL (~42.32 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.22 mg/mL (4.23 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.2 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.22 mg/mL (4.23 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 22.2 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9045 mL | 9.5224 mL | 19.0447 mL | |
| 5 mM | 0.3809 mL | 1.9045 mL | 3.8089 mL | |
| 10 mM | 0.1904 mL | 0.9522 mL | 1.9045 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
